Matthew Gantz is the founder of Castle Creek Biosciences. Castle Creek Biosciences has raised $75M in total funding. Latest round: Growth.
Matthew Gantz serves as President and Chief Executive Officer of Castle Creek Biosciences, a late-clinical stage regenerative medicine company focused on severe skin and connective tissue disorders. He leads the company's Phase 3 clinical study for D-Fi (FCX-007), its lead candidate for dystrophic epidermolysis bullosa.
Full founder directory · Investor directory · Company funding database · Fundraising library